Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score.
Immunoscore
colorectal cancer
host response
tumour budding
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
05
04
2019
accepted:
25
09
2019
pubmed:
29
9
2019
medline:
2
12
2020
entrez:
28
9
2019
Statut:
ppublish
Résumé
The tumour-node-metastasis classification system is used for prognostication purposes and to guide patient management. However, in colorectal cancer (CRC), additional markers are needed to stratify prognostic subgroups. Two promising markers have emerged from large bodies of research: tumour budding and T cell host response (CD3, CD8 and CD45RO infiltrates). However, attempts to combine these two parameters have been sparse. The aim of this study was to perform an assessment of potential protagonists that could be used in a combined score (budding/T cell score, BTS). This descriptive, retrospective study was performed on a multipunch tissue microarray containing material from 345 patients with stages I-IV CRC. Areas from tumour centre, front and microenvironment were stained for pancytokeratin/CD3, pancytokeratin/CD8 and pancytokeratin/CD45RO. Tumour buds were scored manually and T cell infiltrates digitally using open-source software. Tumour buds, T cell counts and combined BTS were associated with clinicopathological features and overall survival (OS). A higher combined BTS score (buds/CD8, tumour centre) performed better than budding or CD8/CD3 alone in predicting nodal metastases (P < 0.0001, OR = 1.466, 95% CI = 1.115-1.928). Only higher BTS (buds/CD3) were significantly associated with poorer OS on multivariate analysis (P = 0.012, hazard ratio = 1.218, 95% confidence interval = 1.044-1.419). Although CD8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-580Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Jessup JM, Goldberg RM, Asare EAet al. Colon and rectum. In Amin MB, ed. AJCC cancer staging manual. 8th ed. New York: Springer Nature, 2017; 251-274.
Brierly JDGM, Wittekind C. TNM classification of malignant tumors. 8th ed. Oxford: Wiley Blackwell, 2017.
Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod. Pathol. 2012; 25; 1315-1325.
De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Arch. 2016; 468; 397-408.
Pages F, Mlecnik B, Marliot F et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391; 2128-2139.
Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the ‘immunoscore’ in the classification of malignant tumours. J. Pathol. 2014; 232; 199-209.
van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Br. J. Cancer 2016; 115; 156-163.
Rogers AC, Winter DC, Heeney A et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br. J. Cancer 2016; 115; 831-840.
Bosch SL, Teerenstra S, de Wilt JH, Cunningham C, Nagtegaal ID. Predicting lymph node metastasis in PT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy 2013; 45; 827-834.
Lugli A, Kirsch R, Ajioka Y et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumour Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 2017; 30; 1299-1311.
Kakar S, Shi C, Berho ME et al. College of American Pathologists: protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Edition 4.0.0.1. Available at: http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-colon-17protocol-4001.pdf (accessed 22 May 2017).
De Smedt L, Palmans S, Andel D et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br. J. Cancer 2017; 116; 58-65.
Dawson H, Lugli A. Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front. Med. 2015; 2; 11.
Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1; 651-661.
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21; 309-322.
De Smedt L, Lemahieu J, Palmans S et al. Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br. J. Cancer 2015; 113; 500-509.
Nosho K, Baba Y, Tanaka N et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 2010; 222; 350-366.
Jass JR, Barker M, Fraser L et al. APC mutation and tumour budding in colorectal cancer. J. Clin. Pathol. 2003; 56; 69-73.
Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 2011; 29; 610-618.
Broussard EK, Disis ML. TNM staging in colorectal cancer: T is for T cell and M is for memory. J. Clin. Oncol. 2011; 29; 601-603.
Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012; 12; 298-306.
Galon J, Pages F, Marincola FM et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 2012; 10; 1.
Lugli A, Karamitopoulou E, Panayiotides I et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer. Br. J. Cancer 2009; 101; 1382-392.
Klintrup K, Makinen JM, Kauppila S et al. Inflammation and prognosis in colorectal cancer. Eur. J. Cancer 2005; 41; 2645-2654.
Rieger G, Koelzer VH, Dawson HE et al. Comprehensive assessment of tumour budding on cytokeratin stains in colorectal cancer. Histopathology 2017; 70; 1044-1051.
Dawson H, Galuppini F, Träger P et al. Validation of the International Tumour Budding Consensus Conference (ITBCC 2016) recommendations on tumor budding in Stage I-IV colorectal cancer. Hum. Pathol. 2019; 85; 145-151.
Dawson H, Koelzer VH, Lukesch AC et al. Loss of CDX2 expression in primary tumors and lymph node metastases is specific for mismatch repair-deficiency in colorectal cancer. Front. Oncol. 2013; 3; 265.
Zlobec I, Koelzer VH, Dawson H, Perren A, Lugli A. Next-generation tissue microarray (NGTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J. Transl. Med. 2013; 11; 104.
Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br. J. Cancer 2013; 108; 2088-2096.
Bankhead P, Loughrey MB, Fernandez JA et al. Qupath: open source software for digital pathology image analysis. Sci. Rep. 2017; 7; 16878.
Eichmann M, Reinhard S, Zlobec I. Scorenado: an efficient and user-friendly visual assessment tool. 4th European Congress on Digital Pathology (ECDP 2018). Helsinki, Finland, 30 May 2018.
Beaton C, Twine CP, Williams GL, Radcliffe AG. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Colorect. Dis. 2013; 15; 788-797.
Petrelli F, Pezzica E, Cabiddu M et al. Tumour budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. J. Gastrointest. Cancer 2015; 46; 212-218.
Benson A, Venook AP, Cederquist L et al.National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (accessed 18 March 2018).
Zlobec I, Minoo P, Terracciano L, Baker K, Lugli A. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology 2011; 59; 482-495.
Lang-Schwarz C, Melcher B, Haumaier F et al. Budding and tumor infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. Hum. Pathol. 2018; 79; 145-151.
Zlobec I, Hadrich M, Dawson H et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br. J. Cancer 2014; 110; 1008-1013.
Lugli A, Vlajnic T, Giger O et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum. Pathol. 2011; 42; 1833-1840.
Bronsert P, Enderle-Ammour K, Bader M et al. Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. J. Pathol. 2014; 234; 410-422.
Zlobec I, Borner M, Lugli A, Inderbitzin D. Role of intra- and peritumoral budding in the interdisciplinary management of rectal cancer patients. Int. J. Surg. Oncol. 2012; 2012; 795945.
Rogers AC, Gibbons D, Hanly AM et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod. Pathol. 2014; 27; 156-162.
Hu G, Wang S. Tumor-infiltrating CD45RO(+) memory T lymphocytes predict favorable clinical outcome in solid tumors. Sci. Rep. 2017; 7; 10376.
Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005; 353; 2654-2666.
Koelzer VH, Lugli A, Dawson H et al. CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. J. Transl. Med. 2014; 12; 81.